MétaCan
Menu
← Back to cohort
Record W4387998434 · doi:10.3389/fimmu.2023.1239132

Mediport use as an acceptable standard for CAR T cell infusion

2023· article· en· W4387998434 on OpenAlexafffund
Maya Eylon, Snehit Prabhu, Samuel John, Maxwell J. M. King, Dhruv Bhatt, Kevin J. Curran, Courtney Erickson, Nicole Karras, Christine L. Phillips, Prakash Satwani, Michelle L. Hermiston, Erica Southworth, Susanne H.C. Baumeister, Julie-An Talano, Margaret L. MacMillan, Jenna Rossoff, Challice L. Bonifant, Gary D. Myers, Rayne H. Rouce, Keri Toner, Timothy A. Driscoll, Emmanuel Katsanis, Dana Salzberg, Deborah Schiff, Satiro De Oliveira, Christian M. Capitini, Holly Pacenta, Thomas Pfeiffer, Niketa C. Shah, Van Huynh, Jodi Skiles, Ellen Fraint, Kevin O. McNerney, Troy C. Quigg, Joerg Krueger, John A. Ligon, Vanessa A. Fabrizio, Christina Baggott, Theodore W. Laetsch, Liora M. Schultz

Bibliographic record

VenueFrontiers in Immunology · 2023
Typearticle
Languageen
FieldMedicine
TopicCAR-T cell therapy research
Canadian institutionsHospital for Sick Children
FundersSidney Kimmel Comprehensive Cancer CenterUniversity of Florida HealthUniversity of California, San FranciscoWinship Cancer InstituteHospital for Sick ChildrenCity of HopeJohns Hopkins UniversityUniversity of MinnesotaUniversity of California, Los AngelesYale UniversityCincinnati Children's Hospital Medical CenterEmory UniversityChildren's National HospitalFlorida Department of Health
KeywordsMedicineChimeric antigen receptorClinical PracticeCell therapyT cellCellImmunologyImmune systemPhysical therapy

Abstract

fetched live from OpenAlex

Introduction: Mediport use as a clinical option for the administration of chimeric antigen receptor T cell (CAR T cell) therapy in patients with B-cell malignancies has yet to be standardized. Concern for mediport dislodgement, cell infiltration, and ineffective therapy delivery to systemic circulation has resulted in variable practice with intravenous administration of CAR T cell therapy. With CAR T cell commercialization, it is important to establish practice standards for CAR T cell delivery. We conducted a study to establish usage patterns of mediports in the clinical setting and provide a standard of care recommendation for mediport use as an acceptable form of access for CAR T cell infusions. Methods: In this retrospective cohort study, data on mediport use and infiltration rate was collected from a survey across 34 medical centers in the Pediatric Real-World CAR Consortium, capturing 504 CAR T cell infusion routes across 489 patients. Data represents the largest, and to our knowledge sole, report on clinical CAR T cell infusion practice patterns since FDA approval and CAR T cell commercialization in 2017. Results: catheters, as accepted standard venous options for CAR T cell infusion. Use of mediports as a standard clinical practice was reported in 29 of 34 sites (85%). Of 489 evaluable patients with reported route of CAR T cell infusion, 184 patients were infused using mediports, with no reported incidences of CAR T cell infiltration. Discussion/Conclusion: Based on current clinical practice, mediports are a commonly utilized form of access for CAR T cell therapy administration. These findings support the safe practice of mediport usage as an accepted standard line option for CAR T cell infusion.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.006
metaresearch head score (Gemma)0.036
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.006
Threshold uncertainty score0.030

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0060.036
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.002
Science and technology studies0.0010.001
Scholarly communication0.0020.002
Open science0.0010.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0040.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.028
GPT teacher head0.323
Teacher spread0.296 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2023
Admission routes2
Has abstractyes

Explore more

Same venueFrontiers in Immunology→Same topicCAR-T cell therapy research→French-language works237,207→